New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 7, 2014
15:30 EDTJNJJohnson & Johnson volatility flat into Q2 and growth outlook
Johnson & Johnson July call option implied volatility is at 14, August is at 13, October is at 12; compared to its 26-week average of 13 according to Track Data, suggesting non-directional price movement into the expected release of Q2 results on July 15.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
08:01 EDTJNJAASLD publishes new recommendations for treating Hepatitis C
Subscribe for More Information
06:33 EDTJNJSevion announces antibody discovery collaboration with Johnson & Johnson
Subscribe for More Information
06:29 EDTJNJGilead drops 4% after Express Scripts picks AbbVie for hepatitis C
Shares of Gilead (GILD) are moving lower in pre-market trading after Express Scripts (ESRX) spokesman Brian Henry told CNBC's Meg Tirrell and other news outlets that the pharmacy benefits manger will exclusively offer AbbVie's (ABBV) recently approved hepatitis C regimen Viekira Pak at a "significant discount" starting Jan. 1. Express Scripts will no longer offer competing drugs from Gilead and Johnson & Johnson (JNJ). Shares of AbbVie are rising 6% to $71.50 in pre-market trading while Gilead is down 4% to $104.15. AbbVie discovered part of the Viekira Pak regimen via its ongoing collaboration with Enanta Pharmaceuticals (ENTA). Shares of Enanta are up 7% to $49.96 in pre-open trading.
06:05 EDTJNJMacroGenics ennters collaboration, license agreement with Janssen
Subscribe for More Information
05:44 EDTJNJExpress Scripts to offer AbbVie hepatitis C drug exclusively, CNBC reports
Express Scripts (ESRX) will offer AbbVie's (ABBV) just approved hepatitis C regimen Viekira Pak at a "significant discount" starting Jan. 1, while excluding competing drugs from Gilead (GILD) and Johnson & Johnson (JNJ), CNBC's Meg Tirrell reports, citing comments from the pharmacy benefits manager's spokesman Brian Henry. Reference Link
December 19, 2014
11:08 EDTJNJJohnson & Johnson receives positive CHMP opinion to extend Velcade indication
Subscribe for More Information
December 17, 2014
09:04 EDTJNJHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information
09:02 EDTJNJHalozyme enters collaboration pact with Janssen for ENHANZE Technology
Subscribe for More Information
08:06 EDTJNJInovio appoints Zane Yang as VP, Clinical Development, Oncology
Subscribe for More Information
December 16, 2014
07:20 EDTJNJGeron announces early HSR clearance for collaboration with Janssen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use